Compare LKFN & IMCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LKFN | IMCR |
|---|---|---|
| Founded | 1872 | 2008 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 1997 | 2021 |
| Metric | LKFN | IMCR |
|---|---|---|
| Price | $59.29 | $36.52 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $67.00 | $67.00 |
| AVG Volume (30 Days) | 143.2K | ★ 333.0K |
| Earning Date | 01-23-2026 | 11-06-2025 |
| Dividend Yield | ★ 3.34% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 3.79 | N/A |
| Revenue | $248,271,000.00 | ★ $379,590,000.00 |
| Revenue This Year | $17.16 | $32.31 |
| Revenue Next Year | $3.98 | $10.50 |
| P/E Ratio | $15.79 | ★ N/A |
| Revenue Growth | 2.85 | ★ 28.11 |
| 52 Week Low | $50.00 | $23.15 |
| 52 Week High | $75.19 | $40.72 |
| Indicator | LKFN | IMCR |
|---|---|---|
| Relative Strength Index (RSI) | 54.41 | 49.05 |
| Support Level | $57.98 | $35.35 |
| Resistance Level | $60.56 | $40.71 |
| Average True Range (ATR) | 1.45 | 1.82 |
| MACD | 0.26 | -0.45 |
| Stochastic Oscillator | 70.89 | 22.55 |
Lakeland Financial Corp is a bank holding company. It provides commercial, retail, wealth advisory, and investment management services. It offers a broad line of products and services throughout its Northern and Central Indiana markets. The company provides commercial and consumer banking services, as well as trust and wealth management, brokerage, and treasury management commercial services. It serves a wide variety of industries including, among others, commercial real estate, manufacturing, agriculture, construction, retail, wholesale, finance and insurance, accommodation and food services, and healthcare.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.